# MARGetuximab Or Trastuzumab (MARGOT)

> **NCT04425018** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 174 (actual)

## Conditions studied

- Breast Cancer
- Stage II Breast Cancer
- Stage III Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Pertuzumab
- **DRUG:** Margetuximab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04425018
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-13
- **Primary completion:** 2024-10-24
- **Final completion:** 2027-07-01
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425018, "MARGetuximab Or Trastuzumab (MARGOT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04425018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*